Elena Elimova

机构：University of Toronto, Princess Margaret Cancer Centre, Institute of Medical Sciences · ORCID：0009-0004-8299-7939

发表论文 257 篇 · 总被引 5583 次 · h-index 30

代表论文

• Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. (2025 · Journal of Clinical Oncology · 被引 50)
• PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer (2025 · Journal of Clinical Oncology · 被引 38)
• Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial (2025 · Nature Communications · 被引 36)
• Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial (2025 · Nature Medicine · 被引 26)
• Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 (2026 · Annals of Oncology · 被引 22)
• Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. (2025 · Journal of Clinical Oncology · 被引 16)